DAMORA THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
DAMORA THERAPEUTICS, INC. (DMRA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $282.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $275.32M.
- DAMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$2.44M.
- DAMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$286.00K.
- DAMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$7.74M.
- DAMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $242.74M.
- DAMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$6.97M.
- DAMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$11.71M.
- DAMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$30.04M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $282.96M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $275.32M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $242.74M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | -$7.29M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$4.68M 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | -$2.44M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$6.97M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | -$2.04M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $1.61M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | -$286.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$11.71M 10-K · filed 2025-03-19 | |||
| 2023-09-30 | -$9.81M 10-Q · filed 2024-11-01 | |||
| 2023-06-30 | -$9.81M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | -$7.74M 10-Q · filed 2024-04-29 | |||
| 2022-12-31 | -$30.04M 10-K · filed 2024-03-08 | |||
| 2022-09-30 | -$32.99M 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$31.88M 10-Q · filed 2023-07-31 | |||
| 2022-03-31 | -$17.00M 10-Q · filed 2023-04-28 | |||
| 2021-12-31 | -$100.36M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | -$96.94M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$94.83M 10-Q · filed 2022-07-29 | |||
| 2021-03-31 | -$88.78M 10-Q · filed 2022-04-29 | |||
| 2020-12-31 | $149.19M 10-K · filed 2022-02-17 | |||
| 2020-09-30 | $71.91M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $24.56M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $31.69M 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | -$19.65M 10-K · filed 2021-03-29 | |||
| 2019-09-30 | -$14.07M 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |